Perinatal stroke in baby, prothrombotic gene in mom: Does this affect maternal health insurance?

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Maternal prothrombotic disorders may contribute to stroke in the fetus before and during birth. Many of the mothers of children with perinatal stroke have no previous history of pathologic thrombosis. Objective: To determine if finding the Factor V Leiden mutation, prothrombin 20210 G-A gene defect, or methylene tetrahydrofolate reductase C677T mutation in an asymptomatic mother of a child with perinatal stroke would affect that mother's ability to obtain health insurance. Methods: 1) The authors reviewed the literature on genetic prothrombotic risk factors and health insurance. 2) The authors surveyed the 17 largest insurance carriers in Indiana to find if diagnosing genetic prothrombotic risk factors in asymptomatic mothers of children with perinatal stroke would affect the mothers' health insurance status. Results: Three articles on genetic prothrombotic risk factors and insurance were identified. Twelve of 17 insurance companies responded to our survey; three had policies on genetic testing. Most companies refused to provide clear, useful information on their policies regarding these risk factors. Conclusions: The authors are currently unable to counsel their patients' families on the long-term insurance implications of screening for genetic prothrombotic risk factors. The insurance implications of diagnosing healthy women with genetic prothrombotic risk factors need further study.

Original languageEnglish
Pages (from-to)13-16
Number of pages4
JournalNeurology
Volume65
Issue number1
DOIs
StatePublished - Jul 12 2005

Fingerprint

Health Insurance
Stroke
Mothers
Insurance
Genes
Genetic Testing
Methylenetetrahydrofolate Reductase (NADPH2)
Insurance Carriers
Mutation
Aptitude
Insurance Coverage
Prothrombin
Health Status
Maternal Health
Fetus
Thrombosis
Parturition

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Perinatal stroke in baby, prothrombotic gene in mom : Does this affect maternal health insurance? / Golomb, Meredith; Garg, Bhuwan P.; Walsh, Larry; Williams, Linda.

In: Neurology, Vol. 65, No. 1, 12.07.2005, p. 13-16.

Research output: Contribution to journalArticle

@article{b88dd915c19548199c1586d0b3dc196f,
title = "Perinatal stroke in baby, prothrombotic gene in mom: Does this affect maternal health insurance?",
abstract = "Background: Maternal prothrombotic disorders may contribute to stroke in the fetus before and during birth. Many of the mothers of children with perinatal stroke have no previous history of pathologic thrombosis. Objective: To determine if finding the Factor V Leiden mutation, prothrombin 20210 G-A gene defect, or methylene tetrahydrofolate reductase C677T mutation in an asymptomatic mother of a child with perinatal stroke would affect that mother's ability to obtain health insurance. Methods: 1) The authors reviewed the literature on genetic prothrombotic risk factors and health insurance. 2) The authors surveyed the 17 largest insurance carriers in Indiana to find if diagnosing genetic prothrombotic risk factors in asymptomatic mothers of children with perinatal stroke would affect the mothers' health insurance status. Results: Three articles on genetic prothrombotic risk factors and insurance were identified. Twelve of 17 insurance companies responded to our survey; three had policies on genetic testing. Most companies refused to provide clear, useful information on their policies regarding these risk factors. Conclusions: The authors are currently unable to counsel their patients' families on the long-term insurance implications of screening for genetic prothrombotic risk factors. The insurance implications of diagnosing healthy women with genetic prothrombotic risk factors need further study.",
author = "Meredith Golomb and Garg, {Bhuwan P.} and Larry Walsh and Linda Williams",
year = "2005",
month = "7",
day = "12",
doi = "10.1212/01.wnl.0000167543.83897.fa",
language = "English",
volume = "65",
pages = "13--16",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Perinatal stroke in baby, prothrombotic gene in mom

T2 - Does this affect maternal health insurance?

AU - Golomb, Meredith

AU - Garg, Bhuwan P.

AU - Walsh, Larry

AU - Williams, Linda

PY - 2005/7/12

Y1 - 2005/7/12

N2 - Background: Maternal prothrombotic disorders may contribute to stroke in the fetus before and during birth. Many of the mothers of children with perinatal stroke have no previous history of pathologic thrombosis. Objective: To determine if finding the Factor V Leiden mutation, prothrombin 20210 G-A gene defect, or methylene tetrahydrofolate reductase C677T mutation in an asymptomatic mother of a child with perinatal stroke would affect that mother's ability to obtain health insurance. Methods: 1) The authors reviewed the literature on genetic prothrombotic risk factors and health insurance. 2) The authors surveyed the 17 largest insurance carriers in Indiana to find if diagnosing genetic prothrombotic risk factors in asymptomatic mothers of children with perinatal stroke would affect the mothers' health insurance status. Results: Three articles on genetic prothrombotic risk factors and insurance were identified. Twelve of 17 insurance companies responded to our survey; three had policies on genetic testing. Most companies refused to provide clear, useful information on their policies regarding these risk factors. Conclusions: The authors are currently unable to counsel their patients' families on the long-term insurance implications of screening for genetic prothrombotic risk factors. The insurance implications of diagnosing healthy women with genetic prothrombotic risk factors need further study.

AB - Background: Maternal prothrombotic disorders may contribute to stroke in the fetus before and during birth. Many of the mothers of children with perinatal stroke have no previous history of pathologic thrombosis. Objective: To determine if finding the Factor V Leiden mutation, prothrombin 20210 G-A gene defect, or methylene tetrahydrofolate reductase C677T mutation in an asymptomatic mother of a child with perinatal stroke would affect that mother's ability to obtain health insurance. Methods: 1) The authors reviewed the literature on genetic prothrombotic risk factors and health insurance. 2) The authors surveyed the 17 largest insurance carriers in Indiana to find if diagnosing genetic prothrombotic risk factors in asymptomatic mothers of children with perinatal stroke would affect the mothers' health insurance status. Results: Three articles on genetic prothrombotic risk factors and insurance were identified. Twelve of 17 insurance companies responded to our survey; three had policies on genetic testing. Most companies refused to provide clear, useful information on their policies regarding these risk factors. Conclusions: The authors are currently unable to counsel their patients' families on the long-term insurance implications of screening for genetic prothrombotic risk factors. The insurance implications of diagnosing healthy women with genetic prothrombotic risk factors need further study.

UR - http://www.scopus.com/inward/record.url?scp=22044447260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044447260&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000167543.83897.fa

DO - 10.1212/01.wnl.0000167543.83897.fa

M3 - Article

C2 - 16009879

AN - SCOPUS:22044447260

VL - 65

SP - 13

EP - 16

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -